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GlycosyltransferaseThe dystroglycanopathies are a group of inherited muscular dystrophies that have a common underlying
mechanism, hypoglycosylation of the extracellular receptor α-dystroglycan. Many of these disorders are also
associated with defects in the central nervous system and the eye. Defects in α-dystroglycan may also play a
role in cancer progression. This review discusses the six dystroglycanopathy genes identiﬁed so far, their
known or proposed roles in dystroglycan glycosylation and their relevance to human disease, and some of
animal models now available for the study of the dystroglycanopathies.
© 2009 Published by Elsevier B.V.1. IntroductionWithin the last eight years, primarily from genetic studies in
humans, it has become clear that a subset of muscular dystrophies
arise due to abnormal glycosylation of dystroglycan, an essential
protein present in the muscle sarcolemmal membrane. Although it
was ﬁrst identiﬁed in the skeletal muscle, dystroglycan has
important roles in other tissues including the central and peripheral
nervous system and epithelial cells [1]. Therefore, it is not surprising
that the number of diseases known to be associated with aberrant
glycosylation of dystroglycan is increasing, and I will also give an
overview of other consequences of disrupting this post-translational
modiﬁcation.
2. The dystroglycanopathies and dystroglycan glycosylation
In humans, recessive mutations in at least six genes result in the
failure of dystroglycan to be properly glycosylated, leading to geneticphy type 1C; WWS, Walker–
rophy; CNS, central nervous
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lsevier B.V.forms of muscular dystrophy. Deﬁciency in dystroglycan glycosylation
is common to all these muscular dystrophies and underlies the
pathogenic mechanisms; hence these disorders are collectively
termed dystroglycanopathies. The dystroglycanopathies range in
severity from Walker–Warburg syndrome (WWS), a severe form of
congenital muscular dystrophy (CMD) that is also associated with
ocular abnormalities and CNS defects [2], to milder forms of limb
girdle muscular dystrophy with no CNS involvement [3]. There is little
correlation between the particular gene mutated and the clinical
picture, instead all the mutations appear to act in a common pathway
and the disease severity is likely to be related to the consequences of a
particular mutation on dystroglycan function.
Dystroglycan (DG) is a core member of the dystrophin associated
glycoprotein complex (the DAPC or DGC), which links the muscle cell
cytoskeleton to the extracellular matrix via dystrophin [4]. The DAPC
acts as a mechanical “shock absorber” and also has a role in cell
signalling [5]. DG is synthesised as a precursor molecular that is post-
translationally cleaved into α- and β-subunits [6]. α- and β-DG
remain non-covalently associated within the DAPC; β-DG is a
transmembrane protein that interacts directly with dystrophin via
its intracellular domain [5], while α-DG is located outside the
membrane and binds the extracellular matrix (ECM) protein laminin
[4]. α-DG has a number of additional ECM ligands, including agrin,
perlecan, neurexin and pikachurin [7–10], all of which bind α-DG via
laminin-G domains [8–10].
α-DG is a heavily (and heterogeneously) glycosylated protein and
it has been known for many years that this glycosylation is necessary
for ligand binding [11]. The heterogeneity, combined with the low
abundance of the protein, has hindered biochemical analysis of the
glycans attached to the protein. The glycobiology of dystroglycan has
recently been detailed in an excellent review [12] and only the key
aspects will be covered here.
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PAGE gels as a heterogeneous band of much larger mass due to the
extensive glycosylation [6]. There are tissue-speciﬁc differences in
both the extent and nature of this glycosylation, resulting in the
apparent mass of the protein varying from 120 kDa in the brain and
peripheral nerve to more than 150 kDa in skeletal and cardiac muscle
[11,13–15]. The majority of the glycans are O-linked and attached to a
central region of the protein (the mucin-like domain) that is rich in
serine and threonine residues. By electron microscopy, α-DG is a
dumbbell-shaped molecule (Fig. 1) with two globular domains
separated a rod-like domain corresponding to this mucin domain [16].
Several groups have used mass spectrometry techniques to
sequence glycans on α-DG puriﬁed from sheep brain [17], cow
peripheral nerve [18] and rabbit skeletal muscle [19]. All these studies
identiﬁedO-mannosyl structures that are rare onmammalian proteins
and are believed to be functionally important for α-DG ligand binding
activity. One particular sialylated O-linked α-mannose structure
[Neu5Ac(α2–3)Gal(β1–4)GlcNAc(β1–2)Man-Ser/Thr]; Fig. 1) has
been proposed to be directly involved in laminin binding [18]. A
number of variants of this structure have also been identiﬁed or
implicated on α-DG [17,20,21]. In combination with the genetic
evidence discussed below, the biochemical data support an essential
role for these O-mannosyl glycans in laminin binding. However, it
should be noted that not all the O-linked sugars on α-DG are attached
via mannose, a substantial proportion contains the more common
core-1 glycan structure Gal(β1–3)GalNAc-Ser/Thr [18,19].
The deﬁciency in α-DG glycosylation in dystroglycanopathies is
observed as a loss of immunoreactivity with one or other of two
commercially available monoclonal antibodies, VIA41 and IIH6 [22–
27]. A polyclonal antibody raised against a hypoglycosylated form of
α-DG identiﬁes a reduced molecular weight form of the protein in the
skeletal muscle from dystroglycanopathy patients [28], supporting the
idea that α-DG is hypoglycosylated in these disorders.
Both VIA41 and IIH6 recognize epitopes that are present only on the
fully glycosylated form of α-DG, although whether the epitopes
themselves are carbohydrates is unclear. In both in vivo and in vitro
studies, immunoreactivity for both mAbs correlates with laminin
binding [28–31], while IIH6 (but not VIA41) blocks this activity [11,32].
These ﬁndings suggest that IIH6 and VIA41 recognize distinct, glycan-
dependent epitopes and demonstrate that there is a close relationship
between these epitopes and the laminin binding site. However,whether
laminin binding is mediated directly by glycans is still unknown.Fig. 1. O-glycan structures on α-dystroglycan. The diagram represents the structures of O-
2Manα-O-Ser/Thr, (B) Galβ1–4(Fucα1–3)GlcNAcβ1–2Manα-O-Ser/Thr and (C) Galβ1–3Ga
involved are indicated with arrows. A key to sugar residues is shown and anomeric conﬁgu3. Dystroglycanopathy genes involved in O-mannosylation
3.1. POMT1 and POMT2
Protein O-mannosyltransferase 1 (POMT1) and 2 (POMT2)
proteins are type III membrane ER-resident proteins [33,34]. They
are related to the yeast Pmt (protein O-mannosyltransferase) proteins
that add a mannose from a dolichol phosphate donor to a Ser/Thr
residue of a protein via an O-linkage [27,34]. The protein O-
mannosyltransferase (PMT) domain responsible for catalytic activity
is located in the N-terminal regions of POMT1 and POMT2. POMT
proteins also contain several conserved mannosyltransferase-IP3R-
RyR (MIR) domains, which are thought to be involved in ligand
binding [35]. POMT1/POMT2 are two of the four Pmt-related genes
identiﬁed in humans. However, the other two genes (SDF2 and
SDF2L1) do not encode Pmt catalytic domains [35]. Together with the
genetic evidence, this supports the idea that POMT1 and POMT2 add
O-linked mannose directly to α-DG in the ER and are responsible for
the initiation of O-mannosyl glycan formation [36].
Co-expression of both POMT1 and POMT2 and formation of a
complex between the two proteins is necessary for O-mannosyl-
transferase activity in mammalian cells [37] and both genes are
broadly expressed in human tissues [33,34], explaining why muta-
tions in one or other gene gives essentially the same phenotype.
Mouse Pomt1 is expressed at highest levels in the developing nervous
system, muscle and eye [38,39], tissues that are the most severely
affected in WWS.
O-mannosylation is rare in mammals and has only been identiﬁed
in a limited number of glycoproteins (including α-DG) in the brain,
nerve and skeletal muscle [40]. Mutations in POMT1 were ﬁrst
identiﬁed in Walker–Warburg Syndrome [WWS; 27], a very severe,
recessive form of CMD that is associated with ocular and retinal
abnormalities and brain defects including type II lissencephaly [2,41].
Subsequently, mutations in POMT2, an obvious candidate gene, were
also shown to be causative for WWS [42,43]. However, WWS is
genetically extremely heterogeneous; only a minority of patients have
point mutations in either POMT1 or POMT2 [44,45]. Although
mutations in the additional dystroglycanopathy genes described
below have been identiﬁed in some of the remaining patients, at
least several WWS loci remain uncharacterized [35].
While the majority of mutations in POMT1 or POMT2 produce
severe,WWS type phenotypes, mutations in these genes can also beenglycans known to be present on α-dystroglycan. (A) Neu5Acα2–3Galβ1–4GlcNAcβ1–
lNAcα-O-Ser/Thr. The steps in which glycosyltransferases discussed in this review are
ration and linkage are marked on bonds.
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disease [46,47] and limb girdle muscular dystrophy [48,49]. A POMT1
mutation has recently been identiﬁed in a patient with bothWWS and
cleft lip and palate [50], further expanding the phenotypes that could
be associated with mutations in this gene. Although most WWS cases
have missense mutations or deletions within the conserved PMT or
MIR domains [35], it is difﬁcult to deﬁne clear genotype/phenotype
correlations [51]. Three POMT1mutations that are causative for WWS,
including two missense mutations G76R and V428D, have been
demonstrated to result in loss of enzymatic activity in cellular
expression assays [52]. However, several mutations leading to milder
forms of CMD or limb girdle muscular dystrophy (G65R, A200P, and
W582C) also show complete loss of enzymatic activity in this cellular
assay [53,54]. Thus, it seems that the phenotypic variation between
POMT1 disease mutations may not be simply due to levels of residual
enzymatic activity and it is possible that genetic variation at other loci
may inﬂuence disease severity.
3.2. POMGnT1
This gene encodes the Golgi-resident protein O-linked mannose
β1, 2 N-acetylglucosaminyltransferase 1, which catalyzes the transfer
of N-acetylglucosamine from UDP-GlcNAc to O-mannosyl glycopro-
teins [55–57]. POMGnT1 therefore acts downstream of POMT1/2 in the
synthesis of O-mannosyl structures on α-DG (Fig. 1). POMGnT1 is
widely expressed in the heart, placenta, lung, liver, kidney and
pancreas, with highest mRNA levels in the skeletal muscle and brain
[56]. Mutations in the human were ﬁrst shown to be causative in
muscle–eye–brain disease (MEB) [56,58]. While MEB is less severe
than WWS, it is also characterized by congenital muscular dystrophy,
brain malformations and ocular abnormalities. As with POMT1/2
mutations in WWS, MEB mutations produce POMGnT1 proteins that
are non-functional when assayed in vitro [56].
The high prevalence of mutations in POMT1/2 or POMGnT1 in the
dystroglycanopathies is strong evidence for an essential role of O-
mannosyl structures for functional α-DG. However, it is still unclear if
laminin binds directly to these O-glycans. It is possible that they are
necessary for additional glycosylation events or they may have a more
structural role, such as enabling α-DG to fold into an appropriate
conformation.
4. Genes of unknown function
This far, the three genes described above are the only dystrogly-
canopathy loci for which biochemical activities of the encoded
proteins have been identiﬁed. Three additional genes required for
functional glycosylation of α-DG (fukutin, FKRP and LARGE) have all
been identiﬁed from genetic studies in humans and mice. Although
sequence homologies for all the proteins encoded by these genes
suggest a role in protein glycosylation, their enzyme activities (if any)
have not yet been deﬁned.
4.1. Fukutin
Mutations in the fukutin gene are mainly associated with
Fukuyama congenital muscular dystrophy (FCMD) [59,60]. In addition
to severe muscle weakness, patients with FCMD almost always have
severe mental retardation, with seizures occurring in about half the
cases [60]. The disease is most prevalent in Japan, where patients carry
at least one copy of an ancestral founder mutation with integration of
a 3 kb retrotransposon element into the 3′ UTR that results in a
reduction in fukutin mRNA levels [60]. Individuals who are homo-
zygous for this mutation are less severely affected than compound
heterozygotes with a point mutation on the other allele, presumably
because they have higher residual levels of functional fukutin [60].
Consistent with this, individuals who are homozygous or compoundheterozygotes for point mutations usually have a more severe WWS-
like disease [61–64]. In a study of 43WWS patients, fukutinmutations
were found to be the most common cause of WWS in European/
American cases [45].
Fukutin is a Golgi-resident protein [59,65]. The presumed catalytic
domain shows similarity to phosphoryl-sugar transferases and
includes a DXD motif that is involved in the coordination of divalent
cations and is characteristic of many glycosyltransferases [66].
However, no enzymatic activity has yet been demonstrated for the
protein. Using co-IP, a physical interaction between fukutin and
POMGnT1 has been reported, suggesting a possible role as a
chaperone or a modiﬁer of POMGnT1 activity [67].
4.2. FKRP
Fukutin related protein (FKRP) was identiﬁed through homology
searches using the Fukutin amino acid sequence [68]. By Northern blot
analysis, FKRP is expressed in a wide range of tissues with highest
levels in the skeletal muscle, placenta and heart [68]. As with Fukutin,
no speciﬁc enzymatic activity has been demonstrated and its role in
α-DG glycosylation is unknown. Mutations in FKRP were originally
identiﬁed in a form of CMD (MDC1C) and in a clinically-deﬁned group
of limb girdle muscular dystrophy patients [25,68]. However, it soon
became apparent that mutations in this gene could also give rise to
much more severe forms of CMD, including WWS and MEB [69].
Some interesting genotype/phenotype correlations have come
from the study of FKRP mutations. A missense mutation L276I is
particularly common in a form of limb girdle muscular dystrophy
(LGMD2I), which has no CNS involvement [25]. This mutation appears
to be hypomorphic and is associated with a relatively mild phenotype
when present in the homozygous state [70,71]. The frequency of this
allele has been estimated to be as high as 1 in 200 in UK and Danish
populations, and 1 in 600 in Germany [25,72]. Such a high frequency is
suggestive of positive selection pressure in heterozygotes and may be
related to the fact that α-DG can act as a viral co-receptor (discussed
below).
The effect of MDC1C-associated mutations in FKRP on the protein
function is unclear. Overexpression of FKRP protein constructs
containing MDC1D mutations mislocalized to the endoplasmic
reticulum in Cos-7 cells [73], indicating that ER retention may play a
role in the pathogenesis of this disease. However, in patients carrying
the same mutations, studies of skeletal muscle biopsies found no
difference in the localization of FKRP compared to control muscle [74].
These conﬂicting results may represent a difference in cellular
localization of FKRP in differentiated muscle compared to other cell
types or simply reﬂect the difﬁculty in replicating the disease situation
in cultured cells. Without knowledge of the function of FKRP, and
therefore an assay of biological activity, it is difﬁcult to draw strong
conclusions about the effects of particular mutations.
In cell culture models, forced co-expression of FKRP and dystro-
glycan in CHO cells appears to alter the post-translational processing
of α-DG. This, undeﬁned, processing event was abolished by co-
expressing dystroglycan with a mutant form of FKRP [65]. This is
consistent with a role for FKRP in modiﬁcation and possibly
glycosylation of α-DG. However, despite the high frequency of
mutations in this gene and its clinical importance, the role of the
protein is currently little understood.
4.3. LARGE
LARGE encodes a putative, bi-functional glycosyltransferase
[75,76]. A role for LARGE in dystroglycan glycosylation was ﬁrst
demonstrated by the identiﬁcation of a loss of function mutation in
this gene in the myodystrophy (myd) mouse mutant [22]. The name
LARGE derives from the fact that this gene, at 650 kb, is the largest
on human chromosome 22 [75]. Indeed, it is one of the largest genes in
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and is contained within only 14 exons.
Perhaps in part as a consequence of the size of the gene, only a few
mutations in LARGE have been reported in human dystroglycanopathy
patients making it difﬁcult to draw conclusions about genotype/
phenotype correlations. A homozygous intragenic deletion predicted
to result in a loss of function was identiﬁed in a patient with WWS
[77], while a less severely affected patient was found to be a
compound heterozygote for a missense and a truncating mutation
[78]. Very recently, a dystroglycanopathy patient was reported to be
homozygous for the missense mutation W495R [79]. This residue lies
within a putative catalytic domain and is absolutely invariant in
vertebrate and invertebrate LARGE proteins. Therefore, this mutation
is likely to disrupt the function of the protein signiﬁcantly.
Vertebrate genomes contain a closely related paralogue of LARGE
called LARGE2 [76,80]. Although overexpression studies indicate that
LARGE2 is likely also to be involved in dystroglycan glycosylation
[80–82], the mRNA has a very different tissue distribution to LARGE
with little or no expression in muscle and brain [80]. Thus, LARGE2
appears not to be a good candidate for involvement in muscular
dystrophy and mutations have not yet been identiﬁed in this gene.
The LARGE protein is predicted to contain an N-terminal
transmembrane anchor, typical of glycosyltransferases. It also has a
predicted coiled coil motif and two presumptive catalytic regions
[22,75]. These two domains are not closely related to each other, each
showing homology to a different family of glycosyltransferases [83].
LARGE is highly conserved, with orthologues in almost all animal
genomes, including sponges and cnidarians, Drosophila being a
notable exception [84].
Although the nature of the enzyme activity remains elusive, a
number of groups have shown that overexpression of LARGE can
induce expression of IIH6 and VIA41 epitopes on dystroglycan and that
this is concomitant with induction of laminin binding activity [30,80–
82, 85]. This activity of LARGE requires a direct interactionwith the N-
terminal domain of α-DG [31]. Co-expression of LARGE and tagged α-
DG deletion constructs showed that amino acids 313–408 within the
mucin domain are also necessary (but not sufﬁcient) for the induction
of the IIH6-positive glycan [31].
The use of Chinese hamster ovary (CHO) cell lines with mutations
in glycosyltransferase pathway genes showed that neither O-mannose
nor high mannose N-glycans were required as a prerequisite for
LARGE activity [85]. Inmutant CHO cells inwhich transfer of galactose,
fucose or sialic acid to glycoconjugates is compromised, LARGE was
still able to induce IIH6-positive dystroglycan glycosylation [85].
Additional data supporting the conclusion that N-glycan structures
are not required comes from a study showing that tunicamycin has no
affect on the activity of exogenously expressed LARGE2 and that
N-glycanase treatment does not reduce the mass of LARGE glycosy-
lated α-DG [82]. Treatment with glycosaminoglycan-degrading
enzymes also failed to remove the IIH6-reactive LARGE dependent
α-DG glycosylation [82]. Thus, the nature of the “IIH6” glycan and the
function of LARGE remain frustratingly elusive.
A remarkable ﬁnding was that even in cells carrying loss of
function mutations in other genes in this pathway such as POMT1 or
POMGnT1 overexpression of LARGE can induce IIH6-positive glycosy-
lation on α-DG [30]. This result has a number of important
implications. It suggests that, at least when overexpressed, LARGE
acts in a different pathway to POMT1 and POMGnT1. This is consistent
with the data from the studies on glycosylation-defective CHO cells
[85]. This ability of LARGE might simply reﬂect promiscuity and an
ability to modify (either directly or indirectly) a wide range of glycan
acceptors. Alternatively, LARGE may induce a rare, uncharacterized
glycan structure on α-DG that is not absolutely dependent on the
presence of O-mannosyl glycans. In either case, upregulation of LARGE
could be a therapeutic strategy for a wide range of dystroglycano-
pathies [30,86]. In vivo studies support this by showing thatelectroporation of LARGE into skeletal muscle can at least partially
rescueα-DG glycosylation and function in fukutin or POMGnT1mutant
mice [87].
5. The relationship between α-DG glycosylation and laminin
binding activity
The genetic data discussed above demonstrate an essential role for
O-mannosyl glycans on α-DG in vivo. This is in agreement with
biochemical data implicating a role for sialylated O-linked sugars in
the laminin binding activity of dystroglycan [88]. The POMT1/2
complex is believed to catalyze the initial attachment of the mannose
to dystroglycan, while POMGnT1 adds the subsequent GlcNAc residue
[55,56]. Whether fukutin, LARGE and FKRP are also involved in
generation of O-mannosyl structures is unclear.
An elegant study interrogated the glycan structures on puriﬁed
skeletal muscle α-DG through a combination of enzymatic deglyco-
sylation followed by analysis of lectin and antibody binding to the
product [89]. Digestion was carried out with a cocktail of glycosidases
that were predicted to reduce the structure Neu5Ac(α2–3)Gal(β1–4)
GlcNAc(β1–2)Manα-O-Ser/Thr to Manα-O-Ser/Thr and completely
remove the core-1 glycan structure Gal(β1–3)GalNAcα-O-Ser/Thr.
Surprisingly, this enzymatic treatment did not abolish laminin-1, IIH6
and VIA41 binding, but rather enhanced it.
This result raises a paradox. The Neu5Ac(α2–3)Gal(β1–4)GlcNAc
(β1–2)Manα-O-Ser/Thr glycan requires POMGnT1 activity and is
presumably absent in dystroglycanopathy patients. This structure has
also been postulated as the structure necessary for the binding of
laminin-1 [18]. However, although there is clear evidence for an in
vivo requirement of this glycan for normal ligand binding, removal by
enzymatic digestion in vitro does not lead to loss of this activity.
In the same study, treatment of α-DG with enzymes that remove
α-linked galactose, N-acetylgalactosamine and fucose, β-linked
glucuronic acid, α- and β-linked mannose also did not reduce
laminin-1 binding or IIH6/VIA41 immunoreactivity. The reactivity of
the remaining epitope with the ConA lectin and its partial resistance
to periodate oxidation treatment led the authors to suggest that a
terminal α-linked GlcNAc is present in the population of glycans on
IIH6-reactive α-DG [89].
Therefore, it is clear that α-DG glycosylation has more complexity
and detail to be uncovered. Meanwhile, the lack of knowledge about
the IIH6 epitope and the biochemical activity of LARGE are serious
impediments to further development in this ﬁeld.
6. Animal models for the study of dystroglycanopathies
A number of animal models are now being developed and
investigated that should provide insights into the molecular, bio-
chemical and developmental pathways that are disrupted in the
dystroglycanopathies. Dystroglycan and most of the genes known to
play a role in glycosylation of the molecule are highly conserved,
allowing both vertebrate and invertebrate organisms to be used.
6.1. Mouse
Dystroglycan (Dag1) null mice are embryonic lethal due to very
early defects in basement membrane assembly [90]. While chimeric
mice can be generated from Dag1−/− ES cells and develop a
progressive severe myopathy [91], Cre-LoxP technology has now
been used extensively by Kevin Campbell's group in Iowa, USA to
produce conditional tissue-speciﬁc knockouts of dystroglycan. Deple-
tion of Dag1 in differentiated skeletal muscle produced a relatively
mild dystrophic phenotype as satellite cells were still able to express
dystroglycan and regenerate muscle ﬁbres [92]. However, elimination
of dystroglycan from the CNS produced a phenotype with striking
similarities to WWS, MEB, FCMD and themydmouse, with disruption
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migration of granule cells [93].
More recently, selective deletion of dystroglycan in the epiblast
(using a Mox2-Cre transgene driver that maintained expression of
dystroglycan in extraembryonic structures) has allowed the genera-
tion of a complete DG-null mouse [94]. A careful and detailed study of
this mouse model showed it to be an excellent model for WWS,
including the ocular pathology [94]. Together, these mouse studies
implicate dystroglycan hypoglycosylation as the major, if not only,
factor underlying the dystroglycanopathy phenotypes.
Not surprisingly, mutation of the mouse orthologues of dystrogly-
canopathy genes rather that dystroglycan itself also leads to
recapitulation of many of the features of these diseases and there
are several spontaneous or engineered mouse models. The myody-
strophy (myd or Largemyd) mouse was ﬁrst noted due to its muscular
dystrophy phenotype [95], and later shown also to show myelination
defects [96]. The myd mutation was shown to be a loss of function
mutation in the Large gene [22]. Subsequently, the myd phenotype
was found also to include neuronal migration abnormalities, retinal
and peripheral nerve defects [28,29], which have subsequently been
studied in more detail [97–101]. Two additional alleles of Large that
result in the same phenotype have also been identiﬁed [102,103].
Two strains of POMGnT1 null mice have been produced. One model
was created by a gene trap disruption of the exon 2 [104], the other
was generated by targeting exon 18 with a neomycin replacement
cassette [105]. Both models have a similar phenotype with myopathy
(which was much milder in the exon 18 targeted mouse), aberrant
glycosylation of dystroglycan and CNS abnormalities. Like the
Largemyd and Fukutin chimeric mice, they exhibit the phenotype of
clasping limbs close to the body when suspended by the tail, show a
reduction in cerebellum size and have neuronal migration defects.
Despite a milder muscle phenotype, the targetedmutant generated by
Miyagoe-Suzuki et al. was associated with a much lower postnatal
survival rate than the exon 2 disruptionmutation, withmore than 60%
homozygotes dying within 3 weeks of birth [105]. This may reﬂect
differences in genetic background, as each strategy appears to have
generated a complete null of POMGnT1.
Fukutin-deﬁcient chimeric mice, generated using embryonic stem
(ES) cells targeted for both fukutin alleles, have a phenotype that
resembles WWS [106]. These mice are viable, but show signiﬁcant
muscle weakness. The mutants also display brain anomalies including
disorganized laminar structures and fusion of the cerebral cortex
hemispheres. They have eye defects reminiscent of those in FCMD,
including abnormal lens development, retinal detachment and retinal
degeneration. A problemwith analysis of this model is that the extent
of chimerism is variable between individual mice. Therefore, a knock-
in mouse was created that contains the human FCMD-associated
retrotransposon targeted into the mouse fukutin 3′ UTR [87].
Although these mice show reduced levels of fukutin mRNA (5–10%
of normal levels) and hypoglycosylation of the majority of skeletal
muscleα-DG, they exhibit no signs of muscular dystrophy, evenwhen
adult. This study demonstrates that in mice at least, only a small
amount of functional α-DG is sufﬁcient for normal muscle function.
In contrast to the Large and PomGnT1 mutants, for most of the
dystroglycanopathy genes knock-out or knock-down strategies pro-
duce a very severe phenotype. Similar to Dag1 knockouts [90], Fukutin
and POMT1 null mice have a very early embryonic lethality due to
abnormal basement membrane formation [38,107]. This is in contrast
to the Fukutin-deﬁcient chimeric mice described above. Ackroyd et al.
recently generated two strains of Fkrp mutant using a knock-in
strategy to replicate a severe human mutation (Tyr307Asn) [108].
Homozygous Fkrp-NeoTyr307Asn mice showed a severe phenotype,
dying soon after birth, with reduced (but not absent) α-DG
glycosylation in muscle and brain. In the neonates, this reduction in
glycosylation was associated with abnormal neuronal migration
within the CNS and reduced muscle mass, although there was noevidence of dystrophic processes. The reduction in Fkrp mRNA levels
appears to be due to the presence of the neomycin cassette in intron 2
as homozygous FkrpTyr307Asn mice showed no phenotype up to
6 months of age. Presumably the Tyr307Asn change, which produces
a severe MEB phenotype in human [69] does not affect the function of
the mouse protein. This study demonstrates the difﬁculty of
generating mouse models of the dystroglycanopathies that accurately
reﬂect the human disorders.
6.2. Zebraﬁsh
The zebraﬁsh is an attractive alternative model system for
functional studies of dystroglycanopathy genes. One advantage of
zebraﬁsh, especially for developmental studies, is the translucent
embryo. In addition, zebraﬁsh embryos have a high proportion of
muscle tissue [109]. An exciting potential of the zebraﬁsh is that it is
suited to large-scale screens for modiﬁer genes and testing of
potential therapeutic reagents.
All the dystroglycanopathy genes identiﬁed so far are conserved in
zebraﬁsh and are present as single copy genes. Furthermore, the
glycan epitopes on α-DG appear also to be conserved [110,111].
Knockdown of FKRP in the zebraﬁsh embryo using morpholino
technology produced muscle, neuronal and eye abnormalities [111].
6.3. Drosophila
POMT1 is the human homologue of the Drosophila rotated abdomen
(rt) gene [33], while POMT2 is the orthologue of twisted; a locus that
shows a genetic interaction with rt [112]. Drosophila POMT1 or POMT2
mutants show abnormal embryonic muscle development [113,114]
and synaptic defects [115]. Co-expression of theDrosophila POMT1 and
POMT2 genes is required for glycosylation of the corresponding
dystroglycan orthologue (Dg) in vitro [116] and in vivo [115]. The
similarities in dystroglycan mannosylation between human and ﬂies
and the ability to carry out large-scale modiﬁer screens using Droso-
phila make this organism an attractive model for identiﬁcation of
additional players in this O-mannosylation pathway. One difference
with this species is that there is no LARGE orthologue, even though
they exist in other invertebrates and in some insects such as bees [80].
Therefore, the post-translational modiﬁcation ofα-DG in Drosophila is
unlikely to be completely analogous to that in humans.
7. Relevance of α-DG glycosylation to other human diseases
7.1. Viral infection
α-DG has previously been identiﬁed as a cellular receptor for
several arenaviruses including lymphocytic choriomeningitis virus
(LCMV) and the human pathogen Lassa fever virus [117]. In these
studies it was observed that binding did not occur on recombinant
proteins but only native proteins, suggesting that post-translational
modiﬁcation such as glycosylation was required. More recently, it was
demonstrated that the virus binding activity of α-DG is dependent on
amino acids 313–408 within the mucin-like domain and that
overexpression of LARGE in cell lines increases LCMV binding and
infectivity [118]. This, viral binding appears to correlate with laminin
binding. Further, virus infectivity was reduced by pre-incubation with
IIH6. This suggests that a common IIH6 and laminin reactive epitope
produced by LARGE is also important for LCMV infectivity [118].
O-mannosylationofα-DG is also important for LCMV infection [119].
Fibroblasts derived from Largemyd mice or fromMEB patients were less
susceptible to infection than control ﬁbroblasts. Cell lines deﬁcient in
general O-mannosylation also showed a reduced infectivity.
This relationship between α-DG glycosylation and viral co-
receptor activity may be an explanation for the high frequency of
some dystroglycanopathy mutations in the general population such as
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fukutin retrotransposon insertion in the Japanese population [60]. It
may be signiﬁcant that both these mutations appear to be hypo-
morphic rather than null alleles. There is also evidence from HapMap
data for positive selection acting on the LARGE gene during human
evolution [120].
7.2. Cancer
Dystroglycan plays an important role in basement membrane and
epithelial assembly via cell contact with the ECM [90,121]. Changes in
α-DG glycosylation may also play a role in cancer progression [122]. A
number of cancers of epithelial and neural origin show an association
between loss ofα-DG and tumour progression, while β-DG expression
is normal indicating that this loss of immunoreactive α-DGmight also
reﬂect changes in glycosylation [123–126].
Several lines of evidence indicate that LARGE may have an
important anti-tumourigenic function. LARGEwas originally identiﬁed
as a gene present in a region of human chromosome 22q frequently
deleted inmeningioma tumours [75]. This locus has also been reported
to be a common fragile site region [127], thus breaks and deletionsmay
often occur within LARGE in tumour cells providing a possible
mechanism for loss of IIH6/VIA41 reactivitywithin tumours. A number
of epithelial cancer cell lines show silencing of LARGE by epigenetic
mechanisms [128]. Moreover, forced expression of LARGE in one of
these cell lines rescued α-DG glycosylation and inhibited both cell
migration and anchorage-dependent growth [128]. There is a high
density of CpG nucleotides in the promoter and 5′ UTR regions of both
the human and mouse LARGE genes [80] and thus epigenetic silencing
may be a common silencing mechanism for this locus in cancer cells.
8. Conclusions
A large number of mutation studies have now been performed for
dystroglycanopathies and it is clear that there is no direct correlation
between the clinical disease presentation and the particular gene
mutated. It is likely that most important factor will be the impact of
the particular mutation on the function of the protein product of that
gene and the downstream consequences for α-DG glycosylation. In
one large study of genotype–phenotype correlations there appeared
to be a general correlation between the extent of α-DG glycosylation
and disease severity [47]. However, this does not hold for all patients
[129] and other factors are clearly important.
Thus far only six dystroglycanopathy genes have been identiﬁed.
Molecular genetic studies have identiﬁed many patients that do not
harbourmutations in any of these genes and therefore other proteins in
this pathway remain to be identiﬁed. It is probable that not all of these
will be related to glycosylationprocesses, as somemay be important for
processing or stability of α-DG. For example a chicken mutant with
muscular dystrophy and loss of α-DG was recently shown to have a
mutation in the ubiquitin ligase gene WWP1 [130], while the Sphynx
catmodel shows a reduction in the overall levels of dystroglycan, but no
changes in glycosylation or ligand binding activity [131].
The identiﬁcation of the elusive LARGE induced glycan(s) has thus
far proved to be a more difﬁcult and frustrating problem than initially
expected. It is to be hoped that further genetic studies of dystrogly-
canopathy patients will identify additional genes that may help to
provide insights into the possible function of LARGE and its role in
post-translational modiﬁcation of α-DG.
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